Trials / Recruiting
RecruitingNCT05498181
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized placebo-controlled clinical trial will evaluate the effect of sacubitril/valsartan (compared with placebo) on echocardiographic measures of hypervolemia, preservation of residual renal function, and key safety parameters in incident hemodialysis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacubitril-valsartan | sacubitril/valsartan |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2026-03-31
- Completion
- 2026-07-30
- First posted
- 2022-08-11
- Last updated
- 2025-11-26
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05498181. Inclusion in this directory is not an endorsement.